Clinical Trial Update: Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effects of Spiolto Respimat (tiotropium/olodaterol) on cardiac function in hyperinflated COPD subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiolto Respimat (tiotropium/olodaterol)

Snippet

Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED